Jpn. J. Pharmacol. 84 (3), 351-354 (2000)

Correction of Hyperglycemia and Insulin Sensitivity by T-1095, an Inhibitor of Renal Na+-Glucose Cotransporters, in Streptozotocin-Induced Diabetic Rats

Akira Oku1, Kiichiro Ueta1, Kenji Arakawa1, Tomomi Kano-Ishihara1, Takeshi Matsumoto1, Tetsuya Adachi2,
Koichiro Yasuda3, Kinsuke Tsuda2, Katsuo Ikezawa1 and Akira Saito1,*

1Discovery Research Laboratory, Tanabe Seiyaku Co., Ltd., 2-2-50 Kawagishi, Toda, Saitama 335-8505, Japan
2Laboratory of Metabolism, Kyoto University Graduate School of Human and Environmental Studies, Sakyo-ku, Kyoto 606-8501, Japan
3Laboratory of Metabolism, Faculty of Integrated Human Studies, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan
*Corresponding author.╩╩FAX:+81-48-433-8161

Abstract: We investigated the effects of T-1095 (3-(benzo[b]furan-5-yl)-2ó,6ó-dihydroxy-4ó-methylpropiophenone 2ó-O-(6-O-methoxycarbonyl)-b-D-glucopyranoside), an orally active inhibitor of Na+-glucose cotransporter, on hyperglycemia and insulin resistance in skeletal muscle of streptozotocin (STZ)-induced diabetic rats. Chronic (4╩weeks) administration of T-1095 as food admixture (0.01-0.1% wt/wt) suppressed the blood glucose level without affecting the food intake and body weight. In addition, the reduced 2-deoxyglucose uptake and lactate release in the soleus muscle of STZ rat was ameliorated by chronic treatment of T-1095. These data suggest that T-1095 improves insulin sensitivity in skeletal muscle through correction of hyperglycemia and has novel therapeutic potential for treatment of diabetes mellitus through removing glucose toxicity.

Keywords: Diabetes-mellitus, Streptozotocin, Na+-glucose cotransporter

Copyrightę The Japanese Pharmacological Society 2000

[Back to TOC]